Sign a contract with UNICEF to supply the next generation polio vaccine, Eupolio, worth $80 million.
LG Chem will start supplying next-generation polio vaccines to solve global public health problems for children.
LG Chem announced on Jan. 7 that it has signed a contract with UNICEF, an international relief organization, to supply a total of $80 million (about 87 billion won) worth of the polio vaccines “Eupolio” from 2021 to 2022, in order to solve the disease.
Eupolio is a next-generation vaccine that has undergone an additional process to chemically eliminate the pathogenicity of the virus by using a weakly toxic virus, and has greater advantages in terms of safety than conventional living vaccines (vaccines using weakly toxic living viruses).”
LG Chem received the world’s first Pre-Qualification (PQ) approval from the WHO in late December for the world’s first “Sabin IPV” vaccine, and signed a large-scale supply contract in just three weeks based on the excellence of its products.
It will start supplying the vaccines from next month in the Middle East, Africa, and 70 Southeast Asian countries.
With this contract, LG Chem will supply more than 20% of UNICEF’s total procurement volume and immediately become a supplier of UNICEF’s Top 3 polio vaccine.
LG Chem is planning to double its production capacity of Eupolio by 2022 to actively contribute to resolving public health problems for children around the world.
“By establishing a global cooperative model with the Bill & Melinda Gates Foundation and UNICEF, LG Chem will play an important role as a major global supplier of polio vaccines,” said Sohn Ji-woong, head of the bio-science business division.
Copyright © Korea IT Times Unauthorized reproduction and redistribution prohibited